Reduce Failure Rates with Better Characterization of MOA with BioMAP®
Phenotypic assays can provide compelling insight into activities and impact of an agent in a target-agnostic manner, however, they frequently require follow-up studies to determine the mechanism of action (MOA). The BioMAP® Phenotypic Profiling Platform utilizes physiologically relevant human primary cell-based disease models to generate a mechanistic fingerprint that is subsequently mined to deconvolute MOA. Our systems biology approach integrates biological responses with mathematical tools to categorize resulting activities with respect to efficacy and safety. Furthermore, our platform can identify polypharmacology as well as secondary or indirect effects of primary target in complex disease models to inform on the potential for clinical efficacy and adverse.
This information provides advantages over typical in-house phenotypic assays by simultaneously integrating target identification with phenotypic characterization, resulting in efficient and actionable results.
Request a Quote
Broad Profiling Detects Clinical Correlations
Database Search Uncovers Mechanistic Similarity
Unsupervised similarity search against BioMAP Reference Database
- Identifies agents with similar activities
- Indicates novel target/MOA or polypharmacology
Reference Database (>4,000 agents)
- Drugs - Clinical stage, approved, failed
- Experimental Chemicals - Research tool compounds, environmental chemicals, nanomaterials
- Biologics - Antibodies, cytokines, factors, peptides, soluble receptors